For the 2017 calendar year, there were 2,044 notified cases of IPD, which was 22% higher when compared with 2016 (n=1,666). The higher levels of IPD observed over the 2017 calendar year, particularly in quarters 2 and 3, may potentially have been influenced by the increased seasonal influenza activity levels that have also been observed over this period.
In the fourth quarter of 2017, there were 415 cases of IPD reported to the National Notifiable Disease Surveillance System (NNDSS). Compared with the number of cases notified in the previous quarter (n=873), this represented a substantial decrease in cases (52%), and compared to the same quarter in 2016 (n=397) there was a 5% increase in the number of cases (Table 1 ). In the fourth quarter of 2017, the most common pneumococcal serotypes causing IPD were 3 (8.9%), 22F (7.7%) and 9N (5.1%) ( Table 2 ). * Based on data extracted from the National Notifiable Diseases Surveillance System (NNDSS) on 18 April 2018. Due to the dynamic nature of the NNDSS, data on this extract is subject to retrospective revision and may vary from data reported in published NNDSS reports and reports of notification data by states and territories.
Among non-Indigenous Australians this quarter, the number of notified cases continued to be highest in children aged less than 5 years and older adult age groups, especially those aged 60 years or older (Table 3) . Among Indigenous Australians, notifications tended to be highest among children aged less than 5 years and adults aged 45 to 49 years, as well as those aged 65 years and over. The proportion of cases reported as Indigenous Australians this quarter (14%; 59/415) was higher compared to the proportion observed in the previous quarter (11%; 97/873) and also in the fourth quarter of 2016 (11%; 45/397) ( Table 1) .
In children aged less than 5 years, there were 65 cases of IPD reported, representing 16% (65/415) of all cases reported in this quarter. The proportion of cases notified in this age group was higher in this reporting period when compared with the previous quarter (11%; 97/873), and similar compared to the proportion reported in the fourth quarter of 2016 (14%; 54/397). Of those cases aged less than 5 years with a known serotype reported this quarter (n=39), 46% (18/39) were due to a serotype included in the 13vPCV, compared to 47% (34/72) of cases in the previous quarter and 57% (24/42) in the fourth quarter of 2016 (Figure 2 ). Of the 18 cases with 13vPCV serotypes in the fourth quarter of 2017, 7 cases were in fully vaccinated children aged less than 5 years and considered to be 13vPCV failures. These 13vPCV failures were due to serotypes 3 (n=6) and 19A (n=1) ( Table 4) . During this quarter the main serotypes affecting children aged less than 5 years were 3 (23%; 9/39) and 19A (13%; 5/39) ( Table 2 ). Both of these serotypes are included in the 13vPCV.
Among Indigenous Australians aged 50 years and over, there were 20 cases of IPD reported this quarter. Of those cases with a reported serotype (n=19), 9 (47%) were due to a serotype included in the 23vPPV, and overall there was no particular serotype dominant (Figure 3 ). The number of notified cases of IPD in this population group was lower than the number of cases reported in the previous quarter (n=33), but higher than the number reported in the fourth quarter of 2016 (n=14).
Among non-Indigenous Australians i aged 65 years and over there were 147 cases of IPD reported this quarter. The number of notified cases of IPD in this population group were 56% lower compared with the number of cases reported in the previous quarter (n=341) and similar to the number reported in the fourth quarter of 2016 (n=142). Of those cases with a reported serotype (n=140), almost 60% (83/140) were due to a serotype included in the 23vPPV (Figure 4) , which was less than the proportion in the previous quarter (62%; 198/319) and also the fourth quarter of 2016 (63%; 86/137). For this quarter, serotypes 3 (n=14), 22F (n=14) and 23A (n=12) were the most common serotypes for this population group. All of these serotypes, except 23A, are included in the 23vPPV.
During this quarter, there were 27 deaths attributed to a variety of IPD serotypes, with serotypes 22F (n=4) and 3 (n=3) being the most common. Almost all of the reported deaths (85%; n=23) occurred in non-Indigenous Australians ii . The median age of those cases reported to have died this quarter was 73 years (range 0 to 96 years).
Notes
The data in this report are provisional and subject to change as laboratory results and additional case information become available. More detailed data analysis of IPD in Australia and surveillance methodology are described in the IPD annual report series published in Communicable Diseases Intelligence.
In Australia, pneumococcal vaccination is recommended as part of routine immunisation for children, individuals with specific underlying conditions associated with increased risk of IPD and older Australians. More information on the scheduling of the pneumococcal vaccination can be found on the Immunise Australia Program website (www.immunise.health.gov.au).
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Diagnosis date (year and quarter) Q2  Q3  Q4  Q1  Q2  Q3  Q4  Q1  Q2  Q3  Q4  Q1  Q2  Q3  Q4  Q1  Q2  Q3  Q4  Q1  Q2  Q3  Q4  Q1  Q2  Q3  Q4  Q1  Q2  Q3  Q4  Q1  Q2  Q3  Q4  Q1  Q2  Q3  Q4   2008  2009  2010  2011  2012  2013  2014  2015  2016 In this report, a 'vaccine failure' is reported when a child aged less than 5 years is diagnosed with IPD due to a serotype found in the 13vPCV and they have received 3 primary scheduled doses of 13vPCV at least 2 weeks prior to disease onset with at least 28 days between doses of vaccine.
There are 3 pneumococcal vaccines available in Australia, each targeting multiple serotypes ( Table 5 ). Note that in this report serotype analysis is generally grouped according to vaccine composition.
Follow-up of all notified cases of IPD is undertaken in all states and territories except New South Wales and Victoria who conduct targeted follow-up of notified cases aged under 5 years, and 50 years or over for enhanced data. Follow-up of notified cases of IPD in Queensland is undertaken in all areas except Metro South and Gold Coast Public Health Units who conduct targeted follow-up of notified cases for those aged under 5 years only. However, in these areas where targeted case follow-up is undertaken, some enhanced data may also be available outside these targeted age groups.
